FARMAKOKINETIK METFORMIN DAN ?-MANGOSTIN PADA PEMBERIAN KOMBINASI DI TIKUS WISTAR JANTAN
Diabetes mellitus (DM) is a metabolic disorder caused by a decrease in insulin secretion and/or a decrease in sensitivity to insulin. Metformin is used as the first-line therapy for non-insulindependent diabetes mellitus (NIDDM) and combination metformin along with herbs are common in the treatmen...
Saved in:
| Main Author: | |
|---|---|
| Format: | Final Project |
| Language: | Indonesia |
| Online Access: | https://digilib.itb.ac.id/gdl/view/44561 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | Diabetes mellitus (DM) is a metabolic disorder caused by a decrease in insulin secretion and/or a
decrease in sensitivity to insulin. Metformin is used as the first-line therapy for non-insulindependent diabetes mellitus (NIDDM) and combination metformin along with herbs are common
in the treatment of NIDDM. One of herbs that have an antihyperglycemic effect is mangosteen
rind extract, which contains ?-mangostin as major constituent. The purpose of this study was to
identify the pharmacokinetics interaction between metformin with ?-mangostin. This current
study was performed using four groups of normal male Wistar rats. Group I only received
metformin, group II only received ?-mangostin, group III received both ?-mangostin and
metformin, and group IV received both ?-mangostin and metformin, where metformin was given
for 10 days. Blood samples were collected at the predetermined sampling points up to 20 hours.
Metformin and ?-mangostin plasma concentrations were analyzed by HPLC and its
pharmacokinetic parameters were determined. In this study, pharmacokinetic parameters of
metformin, such as ?(0.120 ± 0.050 h
-1
for group I, 0.073 ± 0.072 h
-1
for group III, and 0.101 ±
0.071 h
-1
for group IV), t1/2?(6.576 ± 2.627 h for group I, 15.839 ± 9.768 h for group III, and 12.680
± 8.647 h for group IV), and AUC0?20 (43.013 ± 11.528 ????ã.í/mL for group I, 55.979 ± 22.469
????ã.í/?????for group III, and 29.154 ± 17.540 ????ã.í/mL for group IV) in both administration (single
¬?¸ ®??ð?¬?ð??) ¸ð¸?’?¸ð»»±??ðã?ð»ð®¬ntly. Pharmacokinetic parameters of ?-mangostin, such as
?(0.034 ± 0.004 h
-1
for group II, 0.029± 0.008 h
-1
for group III, and 0.031 ± 0.003 h
-1
for group IV),
t1/2?(20.385 ± 2.692 h for group II, 25.184 ± 5.384 h for group III, and 22.254 ± 2.202 h for group
IV), and AUC0??(6.263 ± 1.809 ????ã.í/mL for group II, 3.763 ± 1.673 ????ã.í/mL for group III, and
6.774 ± 5.116 ????ã.í/mL for group IV) ð???í ¬¸?ð?ð???¬?ð??(?ð?ã?± ¬?¸ ®??ð?¬?ð??) ¸ð¸?’?¸ð»»±?
significantly. Administration of metformin at dose of 100 mg/kg along with ?-mangostin at dose
?» 37.2 ?ã/ÿã ð??¬?¸ð¸?’??í???í¬??¬®?ÿð?±?ð® ð??±?¬®?ð???.
Keywords: Metformin, ?-mangostin, diabetes mellitus, pharmacokinetics, drug interactions
|
|---|